Why Biotech ETFs are Rising

Videos
Increasing M&A deals and cutting edge therapies are driving biotech ETFs higher.

IShares Nasdaq Biotechnology ETF: https://www.zacks.com/funds/etf/IBB/profile?cid=CS-YOUTUBE-FT-VID
SPDR S&P Biotech ETF: https://www.zacks.com/funds/etf/XBI/profile?cid=CS-YOUTUBE-FT-VID
ARK Genomic Revolution ETF: https://www.zacks.com/funds/etf/ARKG/profile?cid=CS-YOUTUBE-FT-VID
Virtus LifeSci Biotech Clinical Trials ETF: https://www.zacks.com/funds/etf/BBC/profile?cid=CS-YOUTUBE-FT-VID
ALPS Medical Breakthroughs ETF: https://www.zacks.com/funds/etf/SBIO/profile?cid=CS-YOUTUBE-FT-VID
Merck: https://www.zacks.com/stock/quote/MRK?cid=CS-YOUTUBE-FT-VID
Biogen: https://www.zacks.com/stock/quote/BIIB?cid=CS-YOUTUBE-FT-VID
Sanofi: https://www.zacks.com/stock/quote/SNY?cid=CS-YOUTUBE-FT-VID
ArQule: https://www.zacks.com/stock/quote/ARQL?cid=CS-YOUTUBE-FT-VID
Synthorx: https://www.zacks.com/stock/quote/THOR?cid=CS-YOUTUBE-FT-VID

Follow us on StockTwits: http://stocktwits.com/ZacksResearch
Follow us on Twitter: https://twitter.com/ZacksResearch
Like us on Facebook: https://www.facebook.com/ZacksInvestmentResearch

Articles You May Like

‘Sigh of relief’: Wall Street welcomes Trump’s pick of Bessent for Treasury
States eye green bonds, superfund and cap-and-invest programs to fund resilient infrastructure needs
Market technicals a boon for muni performance in November
Anatomy of a deal: California Community Choice authority’s ESG winner
SEC more than doubles muni enforcement filings in FY 2024